Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TGM2 | P21980 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.39 |
| ▸ | F13A1 | P00488 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TGM1 | P22735 | 1/20 | 0.39 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7789704 | 0.86 | MEN1 (0.32) | MEN1KMT2ALMNA | |
| SCHEMBL428216 | 0.76 | MEN1 (0.48) | MEN1KMT2ACA1CA2ALDH1A1 | |
| SCHEMBL1712020 | 0.74 | MAPT (0.46) | MEN1KMT2ACA1CA2ALDH1A1 | |
| SCHEMBL225711 | 0.74 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1TGM2IDO1 | |
| SCHEMBL3083945 | 0.74 | CYP2A6 (0.42) | MEN1KMT2ACA1CA2CYP2A6 | |
| SCHEMBL3189362 | 0.74 | CYP2A6 (0.42) | MEN1KMT2ACA1CA2CYP2A6 | |
| SCHEMBL1486303 | 0.74 | NPC1 (0.43) | MEN1KMT2ACA1CA2CYP2A6 | |
| SCHEMBL1318227 | 0.74 | ALDH1A1 (0.44) | MEN1KMT2ACA1CA2MAOA | |
| SCHEMBL5537273 | 0.74 | TSHR (0.43) | MEN1KMT2ACA1CA2ALDH1A1 | |
| SCHEMBL2095171 | 0.74 | CA1 (0.43) | CA1CA2IDO1CA12MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109843283-A | Urea derivative | 第一三共株式会社 | 2019-06-04 | — | — | CN | claimed |
| US-6380197-B1 | FOR TREATING AND PREVENTING A PLETHORA OF DISEASES INCLUDING DIABETES | AVENTIS PHARMA S. A. (FR) | 2002-04-30 | — | — | US | claimed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| EP-1001943-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2000-05-24 | — | — | EP | claimed |
| WO-1999003843-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1999-01-28 | — | — | WO | claimed |
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| CN-110279684-B | Use of formyl peptide receptor 2 agonists for the treatment of ocular inflammatory diseases | 阿勒根公司 | 2023-02-28 | — | — | CN | disclosed |
| EP-3795148-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-10899780-B2 | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases | ALLERGAN, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-20210008085-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN INC (US) | 2021-01-14 | — | — | US | disclosed |
| US-20210000846-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN INC (US) | 2021-01-07 | — | — | US | disclosed |
| US-4232030-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1980-11-04 | — | — | US | disclosed |
| US-4194047-A | Substituted N-methylene derivatives of thienamycin | MERCK & CO., INC. (US) | 1980-03-18 | — | — | US | disclosed |
| EP-0001264-A1 | Substituted N-methylene derivatives of thienamycin sulfoxide and sulfone and their preparation | MERCK & CO. INC. (US) | 1979-04-04 | — | — | EP | disclosed |
| US-4140860-A | BACTERICIDES | STERLING DRUG INC. (US) | 1979-02-20 | — | — | US | disclosed |
| US-4119668-A | ANTIBACTERIAL AGENTS | STERLING DRUG INC. (US) | 1978-10-10 | — | — | US | disclosed |
| US-4085144-A | ANTIBACTERIAL | STERLING DRUG INC. (US) | 1978-04-18 | — | — | US | disclosed |
| US-4022833-A | ANTIBACTERIAL AGENTS | STERLING DRUG INC. (US) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008085-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | MEN1 4375/4885KMT2A 4486/4885CA1 4828/4885 |
| US-20210000846-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | MEN1 4375/4885KMT2A 4486/4885CA1 4828/4885 |
| US-10899780-B2 | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases | FPR2, FPR1, FPR3 | MEN1 4240/4885KMT2A 4567/4885CA1 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.